MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$619,929
EPS
-$0.01
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
255,479
225,479
146,500*
-
General and administrative
189,121
213,974
413,986*
159,131
General and administrative affiliates
210,000
1,493,600
201,897*
336,874
Total operating expenses
654,600
1,933,053
762,383
496,005
Loss from operations
-654,600
-1,933,053
-762,383*
-496,005
Change in fair value (fv) of derivative
106,759
-73,136
-974,597.75*
264,796
Interest expense
36,126
35,729
34,363*
36,522
Interest expense affiliates
30,382
24,963
12,840*
10,759
Amortization of intellectual property
-
2,108
1,426.5*
4,236
Debt forgiveness
-
-
33,466.75*
-
Amortization of ip
5,580
-
-
-
Total other income (expenses)
34,671
-135,936
-989,760.5*
213,279
Net income (loss) before provision for income taxes
-619,929
-2,068,989
-1,752,143.5
-282,726
Net income (loss)
-619,929
-2,068,989
-1,752,143.5
-282,726
Net income (loss) attributable to bioxytran
-619,929
-2,068,989
-1,752,143.5
-282,726
Basic EPS
-0.01
-0.02
-0.018
0
Diluted EPS
-0.01
-0.02
-0.018
0
Basic Average Shares
114,355,933
112,283,387
97,698,262
88,992,242
Diluted Average Shares
114,355,933
112,283,387
97,698,262
88,992,242
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net income (loss)
attributable to bioxytran
-$619,929
(-1849.38%↓ Y/Y)
Net income (loss)
-$619,929
(-1849.38%↓ Y/Y)
Change in fair value
(fv) of derivative
$106,759
(-65.27%↓ Y/Y)
Net income (loss)
before provision for...
-$619,929
(-1849.38%↓ Y/Y)
Total other income
(expenses)
$34,671
(-86.64%↓ Y/Y)
Interest expense
$36,126
(19.97%↑ Y/Y)
Interest expense
affiliates
$30,382
(99.03%↑ Y/Y)
Amortization of ip
$5,580
(122.40%↑ Y/Y)
Loss from operations
-$654,600
(-192.13%↓ Y/Y)
Total operating
expenses
$654,600
(192.13%↑ Y/Y)
Research and development
$255,479
(149.25%↑ Y/Y)
General and
administrative affiliates
$210,000
(852.47%↑ Y/Y)
General and
administrative
$189,121
(90.01%↑ Y/Y)
Buy us a coffee
BIOXYTRAN, INC (BIXT)
BIOXYTRAN, INC (BIXT)